# Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

> **NCT03121846** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Soft Tissue Sarcoma, Adult, Stage II

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03121846
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2018-11-01
- **Final completion:** 2019-05-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121846, "Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03121846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*